AOD9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
"The Science of Addiction: Genetics and the Brain". learn.genetics.utah.edu. Learn.Genetics – University of Utah. Why do our brains get addicted? – a TEDMED 2014 talk by Nora Volkow, the director of the National Institute on Drug Abuse at NIH. Kyoto Encyclopedia of Genes and Genomes (KEGG) signal transduction pathways: KEGG – human alcohol addiction KEGG – human amphetamine addiction KEGG – human cocaine addiction
== Pathogenesis == In susceptible persons, beryllium exposure can lead to a cell-mediated immune response. The T-cells become sensitized to beryllium. Each subsequent exposure leads to an immune response involving CD4+ helper T-lymphocytes and macrophages accumulating in the lungs. As this response continues macrophages, CD4+ T-lymphocytes and plasma cells aggregate together to form the noncaseating granulomas. When beryllium is phagocytized by macrophages, the beryllium triggers macrophage apoptosis, thereby reducing beryllium clearance from the lungs and eventually resulting in secondary necrosis and lysis. Eventually, the outcome is fibrosis of the lung. Several studies have shown that there is a genetic component to beryllium sensitivity. Specifically, those beryllium-exposed workers with a mutation at the HLA-DPB1 Glu69 position have increased prevalence of beryllium sensitization and chronic beryllium disease. The HLA-DPB1 gene is important for MHC class II molecule function on antigen presenting cells. A study of the immune response to beryllium in individuals who express the HLA-DP2 allele found that CD4 T-cells do not detect the Be2+ cation itself, but instead detect surface changes in the HLA-DP2/peptide complex in which Be2+ is embedded. Those researchers concluded that chronic beryllium disease is a predisposition that lies between "allergic hypersensitivity and autoimmunity." According to the International Agency for Research on Cancer, beryllium and beryllium compounds are Category 1 carcinogens; they are carcinogenic to both animals and humans.
=== Weight loss === Excess body weight is thought to be an important cause of sleep apnea. People who are overweight have more tissues in the back of their throat which can restrict the airway, especially when sleeping. In weight loss studies of overweight individuals, those who lose weight show reduced apnea frequencies and improved apnoea–hypopnoea index (AHI). Weight loss effective enough to relieve obesity hypoventilation syndrome (OHS) must be 25–30% of body weight. For some obese people, it can be difficult to achieve and maintain this result without bariatric surgery.
== Structure == Spiroligomer molecules can be synthesized in any direction, and between any pair of bis-amino acids. Spiroligomer diketopiperazines can be created between either end of a bis-amino acid. Spiroligomer molecules are known to be conformationally rigid, due to the fused-ring backbone.
Sources: en.wikipedia.org
genetic block A reduction in the activity of a particular enzyme in a metabolic pathway as a result of a mutation in the gene(s) encoding that enzyme, such that all subsequent steps in the pathway are effectively "blocked" from completion. A genetic block is said to be complete when the particular enzymatic activity is entirely absent, and incomplete or leaky when activity is present but defective or proceeds only at a limited rate.
=== Background === Early methods of secondary structure prediction, introduced in the 1960s and early 1970s, focused on identifying likely alpha helices and were based mainly on helix-coil transition models. Significantly more accurate predictions that included beta sheets were introduced in the 1970s and relied on statistical assessments based on probability parameters derived from known solved structures. These methods, applied to a single sequence, are typically at most about 60–65% accurate, and often underpredict beta sheets. Since the 1980s, artificial neural networks have been applied to the prediction of protein structures. The evolutionary conservation of secondary structures can be exploited by simultaneously assessing many homologous sequences in a multiple sequence alignment, by calculating the net secondary structure propensity of an aligned column of amino acids. In concert with larger databases of known protein structures and modern machine learning methods such as neural nets and support vector machines, these methods can achieve up to 80% overall accuracy in globular proteins. The theoretical upper limit of accuracy is around 90%, partly due to idiosyncrasies in DSSP assignment near the ends of secondary structures, where local conformations vary under native conditions but may be forced to assume a single conformation in crystals due to packing constraints.
The European Union conducts cyber war game scenarios with member states and foreign partner states to improve readiness, skills and observe how strategic and tactical decisions may affect the scenario. As well as war games which serve a broader purpose to explore options and improve skills, cyber war games are targeted at preparing for specific threats. In 2018 the Sunday Times reported the UK government was conducting cyber war games which could "blackout Moscow". These types of war games move beyond defensive preparedness, as previously described above and onto preparing offensive capabilities which can be used as deterrence, or for "war".
Hart (1874–1953), American biochemist at the University of Wisconsin-Madison who studied farm animal diet. Brian S. Hartley FRS (1926–2021). British biochemist at Imperial College London. Known for studies on chymotrypsin and other proteolytic enzymes. Hamilton Hartridge FRS (1886–1976). British eye physiologist known in biochemistry for the continuous-flow method for following fast reactions. Demis Hassabis (b. 1976). British computer scientist and artificial intelligence researcher at University College London. Nobel Prize in chemistry 2024. Reinhart Heinrich (1946–2006). German biophysicist at the Humboldt University of Berlin, noted for the origin and development of metabolic control analysis. Max Henius (1859–1935). Danish-American biochemist who specialized in fermentation processes. Founder of the Chicago-based American Brewing Academy. Victor Henri (1872–1940). French physical chemist of Russian parents at the University of Liège. He was the first to apply ideas of physical chemistry to the properties of enzymes. Avram Hershko (b. 1937 as Herskó Ferenc). Hungarian-Israeli biochemist at the Technion (Haifa), known for the discovery of ubiquitin-mediated protein degradation. Nobel Prize in Chemistry (2004). Foreign associate Natl. Acad. Sci. USA.
UNC Rex Hospital is a general hospital located in Raleigh, North Carolina. It is the capital city's oldest hospital, founded by a bequest from John T. Rex (1771–1839), a local tanner, planter, and owner of enslaved families, and named in his honor. Originally located on what is now Dorothea Dix campus, and later on St. Mary's Street, Rex is now located in west Raleigh at the corner of Blue Ridge Road and Lake Boone Trail. Rex Health Care's services include oncology, heart and vascular, surgical services (including bariatric, heartburn, GI, orthopedic, neuro, and spinal), rehabilitation, emergency department, urgent care, women's services, and wound healing. Rex is a member of the UNC Health Care system, a non-profit integrated health care system, owned by the state of North Carolina and based in Chapel Hill, North Carolina. Rex is located just 2 miles from the Lenovo Center, and is the official healthcare provider of the Carolina Hurricanes and NC State Wolfpack.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.